Pharmacogenetic study in patients treated with anti-smoking drug

• Grant number: 11/15332-3
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: October 01, 2011
• End date: September 30, 2012
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Paulo Caleb Júnior de Lima Santos
• Grantee: Paulo Roberto Xavier Tomaz
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

Smoking is one of the more important risk factors for cardiovascular disease and it has remained a cause of death worldwide. The anti-smoking drug is the main toll of treatment antitabagism. In recent decades, these drugs were largely responsible for reductions in the prevalence of smokers. Some pharmacogenetic tests are now available to healthcare professionals and patients, and increasingly, regulatory agencies comply with the technological advances and, thus, understanding the relationship between drug genomics. The main aim of this study is to associate drug treatment and polymorphisms with therapeutic efficiency, or with episodes of adverse effects. Analysis of the genotypes will be performed by amplification of genomic DNA by polymerase chain reaction (PCR) followed by melting curves analysis (HRM). The expected results may reveal associations between the studied markers and conditions for effective therapeutic or adverse effects. This information may be useful in designing preventive and therapeutic tools for personalized medicine in our public service.(AU)